Jun 3 |
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
|
May 22 |
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
|
May 14 |
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
|
May 13 |
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
|
May 13 |
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
|
May 13 |
UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M
|
May 13 |
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
|
May 12 |
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
|
May 10 |
UroGen Pharma Q1 2024 Earnings Preview
|
May 5 |
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
|